Rifabutin use in staphylococcus biofilm infections: A case series
Abstract
This is a case series of 10 patients who had staphylococcal biofilm infections that were treated with adjuvant rifabutin therapy instead of rifampin therapy. In these cases, rifampin was contraindicated secondary to drug–drug interactions with the patients’ chronic medications. Rifabutin therapy was well tolerated with no side effects. As well, no patients had recurrence of their staphylococcal infections. This case series shows that rifabutin can be a beneficial adjuvant therapy in Staphylococcus biofilm infections when drug–drug interactions limit the use of rifampin. © 2020 by the authors.Identifier to cite or link to this item
http://hdl.handle.net/10713/13606ae974a485f413a2113503eed53cd6c53
10.3390/antibiotics9060326